Navigation Links
Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
Date:3/31/2009

ASHBURN, Va., March 31 /PRNewswire/ --- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has filed a US 510k application for its CollaRx(TM) Lidocaine Sponge for the management of painful wounds.

It is estimated that each year 13 million patients worldwide suffer from chronic wounds (venous stasis ulcers, pressure ulcers, diabetic foot ulcers, etc.) 35 percent of all chronic wounds do not heal within 5 years. Patients suffering from wound pain have been difficult to assess and have been regularly undertreated. However, it is estimated that 6 out of every 10 chronic wound patients suffer from pain associated with their wounds, and if left untreated, this pain can lead to depression, loss of appetite, and immobility, all of which have a further negative impact on the rate of healing of the wound.

The CollaRx Lidocaine Sponge is a lyophilized collagen sponge containing purified type-I collagen protein and lidocaine, a locally acting anesthetic. The product is intended to be used for the management of painful wounds including: diabetic ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular etiologies, full-thickness & partial thickness wounds, abrasions, traumatic wounds, 1st and 2nd degree burns and dehisced surgical wounds.

Dr. Michael Myers, President and CEO commented, "I am very pleased about the progress that we have made with the CollaRx Lidocaine Sponge. This marks our third medical device filing in the US, and demonstrates the versatility of our collagen based drug delivery technology."

About CollaRx

CollaRx is Innocoll's lead technology platform for the site specific targeted delivery of a wide variety of medicines with particular emphasis on antibiotics and anesthetics. The CollaRx technology also forms the basis of Innocoll Pharmaceuticals' lead product, Gentamicin Surgical Implant, a biodegradable l
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
2. Renowned Stem Cell Researcher Files Study Results With Stemedica
3. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
4. Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
7. Tigris Pharmaceuticals Files IND Application for GGTI-2418
8. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
9. Stem Cell Innovations, Inc., Files New Patent Application
10. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
11. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... N.J., Nov. 13 Soligenix, Inc., (Soligenix or ... as DOR BioPharma, Inc., a late-stage biotechnology company, ... quarter of 2009. , Highlights and ... enrollment in its confirmatory Phase 3 randomized, double-blind, ...
... ... System that addresses common problems associated with purification of recombinant proteins by enabling ... , ... Madison, WI (PRWEB) November 12, 2009 -- The recently released Promega HaloTag® Protein ...
... Exchange Symbol: MS , EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - ... operational results for the three and nine months ended ... license and collaboration agreement between BioMS Medical and Eli ... with the effect that all commercial rights to dirucotide ...
Cached Biology Technology:Soligenix Reports Third Quarter 2009 Financial Results 2Soligenix Reports Third Quarter 2009 Financial Results 3Soligenix Reports Third Quarter 2009 Financial Results 4Soligenix Reports Third Quarter 2009 Financial Results 5Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins 2BioMS Medical Announces Third Quarter 2009 Results 2BioMS Medical Announces Third Quarter 2009 Results 3BioMS Medical Announces Third Quarter 2009 Results 4BioMS Medical Announces Third Quarter 2009 Results 5BioMS Medical Announces Third Quarter 2009 Results 6BioMS Medical Announces Third Quarter 2009 Results 7BioMS Medical Announces Third Quarter 2009 Results 8
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... available in Spanish . Studies by ... presence of Escherichia coli pathogens in surface waters ... in underwater sediments. Most E. coli strains ... water quality managers to estimate fecal contamination. These findings, ...
... of years ago, humans discovered flammable gas could be produced ... anaerobic digestion. Today, EU laws are pushing governments to use ... to enrich soil or biogas for energy. Our environment would ... dumped in diminishing landfill sites. However, while the scientific ...
... have filled an important gap in the study of tunicate ... gelatinous, free-swimming types of tunicates. Their study was featured on ... of Plankton Research . Tunicates are a phylum of ... covering called a tunic, from which the name derives. ...
Cached Biology News:E. coli can survive in streambed sediments for months 2Time to make more out of waste 2Time to make more out of waste 3Woods Hole Oceanographic Institution study sheds light on tunicate evolution 2
... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... Biochain's plant total protein ... for rapidly screening tissue specific ... Human placenta total protein is ... an interblot control for comparison ...
Biology Products: